Women with isolated metastatic carcinoma or adenocarcinoma involving axillary lymph nodes are a well-recognized group of unknown primary carcnoma (UPC) patients with a favorable prognosis. This group of patients are generally treated based on the assumption that they have occult breast cancer. However, to facilitate patient access to the whole spectrum of therapies available for patients with breast cancer, including strategies involving the use of high-dose chemotherapy, a precise diagnosis is increasingly important. In this clinical case we report the detection of a primary breast cancer by 11! In-pentetreotide scanning in a woman who presented with metastatic carcinoma in axillary nodes, no palpable breast lesion, a nondiagnostic mammogram, and negative breast ultrasonography.
Introduction
Patients with metastatic carcinomas of unknown primary origin generally have a poor survival rate and are frequently nonresponsive to chemotherapy. However, subgroups with favorable outcomes have been identified based on clinical presentations and on specific pathologic characteristics. One such subgroup includes women who present with isolated metastatic carcinoma or adenocarcinoma involving axillary lymph nodes. This group of patients are generally treated based on the assumption that they have occult breast cancer [1] . Although the survival statistics for this group are similar to those of women with stage II/III breast cancer, pathologic examination of the ipsilateral breast removed by mastectomy detects a primary tumor in only 40%-70% of the patients [2] [3] [4] [5] .
Breast cancer is highly responsive to numerous chemotherapy drugs. High-dose chemotherapy combined with bone marrow transplantation or autologous peripheral stem cell support has been associated with prolonged progression-free survival in patients with metastatic disease [6] [7] [8] [9] . A precise diagnosis is therefore extremely important, facilitating patient access to the whole spectrum of available therapies, including strategies involving the use of high-dose chemotherapy.
The development of '"in-pentetreotide scanning has increased our ability to detect malignancies expressing somatostatin receptors. In a study of 50 patients with pathologically confirmed primary breast cancer, 75% of the primary tumors were demonstrated by In-pentetreotide scanning [10] . In this clinical case we report the detection of a primary breast cancer by lu In-pentetreotide scanning in a patient who presented with metastatic carcinoma in axillary nodes, no palpable breast lesion, a nondiagnostic mammogram, and negative breast ultrasonography.
Case history
A 46-year-old woman presented with a four-month history of left axillary adenopathy. An excisional biopsy of a left axillary mass showed a metastatic adenocarcinoma. On physical examination, she had multiple enlarged left axillary nodes measuring between 1 and 3 cm in maximum diameter. Silicone breast implants were present. No palpable mass distinct from the implants was appreciated in either breast by four different examiners. A mammogram showed a diffuse increase in parenchymal density and no mass in either breast ( Figure 1A) . A breast ultrasound showed enlarged left axillary nodes, but no mass effect ( Figure IB ). An "'in-pentetreotide nuclear scan was then performed. Intense focal uptake was detected at four hours ( Figure 1C somatostatin-receptor-positive primary carcinoma of the upper outer quadrant of the left breast with axillary node metastases. The right breast showed slightly increased diffuse uptake ( Figure 1C ) that failed to increase in intensity at 24 hours ( Figure ID) , and was possibly associated with the implant. A bone scan showed no evidence of metastatic lesions. The clinical impression was that the patient had a primary carcinoma of the left breast, stage IIIA (TX N2 MO).
The patient was subsequently treated with a doxorubicin-based chemotherapy regimen. There was no response after two courses of treatment, therefore a left modified radical mastectomy was recommended. Palpation of the breasts while the patient was under general anesthesia agains did not reveal a mass. Pathologic examination of the mastectomy specimen revealed a diffuse 9.5 x 6.0 x 2.0 cm invasive ductal carcinoma of the left breast; Black's nuclear grade 1. Thirty-one of 34 lymph nodes examined were found to be positive for metastatic carcinoma. The patient received two courses of postoperative chemotherapy with paclitaxel and was then entered into a clinical study of high-dose chemotherapy with autologous stem cell transplantation.
Comments

11
'in-labeled pentetreotide scanning can identify primary tumors of neuroendocrine lineage undetected by conventional imaging modalities [11, 12] . The expression of somatostatin receptors by non-neuroendocrine malignancies such as breast, lung, brain, and lymphatic neoplasms has further extended the applications of this technique [13] . In breast cancer, approximately 70% of the tumors express somatostatin receptors and can be imaged successfully. A higher detection rate for T2 (> 2 and < 5 cm) than for Tl (< 2 cm) primaries (86% vs. 61%) has also been reported [10] . The finding at pathologic examination of primary breast tumors that were undetected notwithstanding a relatively large size has been previously reported in the surgical literature [14] , and frequently involved large (5 to 5.5 cm in maximum diameter) diffusely infiltrating tumors [10, 14] .
As a manifestation of unknown primary carcinoma, isolated axillary adenopathy secondary to metastatic adenocarcinoma or carcinoma is not rare [15] . This presentation of UPC often occurs in women and has unique clinical features [16] . As noted previously, many of these women have occult breast primaries but it may be impossible to identify the primary even following pathologic examination of the mastectomy specimen as much as 30%-60% of the time [2] [3] [4] [5] . In this setting many investigators recommend re-biopsy of involved axillary nodes for estrogen and progesterone levels. In view of the influence of this information on diagnosis and management, a positive result is often considered highly supportive of the diagnosis of occult breast cancer.
Even in the absence of a definitive diagnosis management of women with UPC and isolated axillary metastases is based on the treatment of breast cancer and should generally include both local and systemic therapies [1] . Older series have advocated modified radical mastectomy and axillary dissection for primary treatment [3] [4] [5] [6] . However, a more contemporary series of 42 patients suggested that survival was superior in patients receiving systemic chemotherapy, and local control was improved by irradiating the breast and axilla [17] . The actuarial disease-free survival reported in that study was 71% at five years and 65% at 10 years. Based on these data, the current approach used at the U.T.M.D. Anderson Cancer Center for the evaluation and management of women with isolated axillary adenopathy is outlined in Figure 2 .
Patients with axillary adenopathy and involvement of additional sites (usually liver and/or bone) or with non-adenocarcinoma histology comprise a much more heterogeneous group composed of equal numbers of men and women as well as a broader histologic spectrum with poorly differentiated carcinoma and neuroendocrine carcinomas represented in addition to adenocarcinoma [16] . Despite this heterogeneity, the survival of patients with axillary adenopathy and other involved organ-sites is intermediate between that of the overall UPC population and women with isolated axillary adenopathy [15] .
While managing women with UPC and isolated axillary adenopathy based on a presumptive diagnosis of breast cancer yields favorable results, establishing a specific diagnosis of breast cancer clearly has increasingly significant implications for local and systemic disease management. New drugs and drug combinations with favorable activity profiles [18] and high-dose chemotherapy regimens with bone marrow transplantation or stem cell support [6] [7] [8] [9] are both available to patients with breast cancer, but access to such treatment generally requires a specific diagnosis.
A contemporary outcomes analysis of patients with unknown primary tumors emphasized the value of identifying women with breast cancer [19] . The current report adds an additional imaging technique to conventional mammography and ultrasonography and suggests that the "'in-pentetreotide scan results can contribute specific, clinically useful information to the evaluation of women presenting with metastatic carcinoma in axillary nodes and an occult primary. This modality appears to be potentially useful in the evaluation of selected patients with UPC, and deserves prospective study in women with UPC presenting with isolated axillary metastases.
